JPH01186835A - イソプレノイド誘導体およびこれを含有する医薬製剤 - Google Patents
イソプレノイド誘導体およびこれを含有する医薬製剤Info
- Publication number
- JPH01186835A JPH01186835A JP902088A JP902088A JPH01186835A JP H01186835 A JPH01186835 A JP H01186835A JP 902088 A JP902088 A JP 902088A JP 902088 A JP902088 A JP 902088A JP H01186835 A JPH01186835 A JP H01186835A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- lipoxygenase
- isoprenoid
- present
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003505 terpenes Chemical class 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims description 22
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 8
- 230000000767 anti-ulcer Effects 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 208000006454 hepatitis Diseases 0.000 abstract description 4
- 231100000283 hepatitis Toxicity 0.000 abstract description 4
- 208000026935 allergic disease Diseases 0.000 abstract description 3
- 208000006673 asthma Diseases 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 201000008383 nephritis Diseases 0.000 abstract description 3
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 abstract description 2
- 150000001299 aldehydes Chemical class 0.000 abstract description 2
- 238000010511 deprotection reaction Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 238000005882 aldol condensation reaction Methods 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 238000006356 dehydrogenation reaction Methods 0.000 abstract 1
- 201000005917 gastric ulcer Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 14
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 231100000397 ulcer Toxicity 0.000 description 8
- 150000002617 leukotrienes Chemical class 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000003699 antiulcer agent Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- 229940043279 diisopropylamine Drugs 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UHEPJGULSIKKTP-UHFFFAOYSA-N sulcatone Chemical compound CC(C)=CCCC(C)=O UHEPJGULSIKKTP-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KGIJOOYOSFUGPC-LJQANCHMSA-N (5s)-5-hydroxyicosa-6,8,11,14-tetraenoic acid Chemical compound CCCCCC=CCC=CCC=CC=C[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-LJQANCHMSA-N 0.000 description 1
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 1
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000005575 aldol reaction Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- HNZUNIKWNYHEJJ-FMIVXFBMSA-N geranyl acetone Chemical compound CC(C)=CCC\C(C)=C\CCC(C)=O HNZUNIKWNYHEJJ-FMIVXFBMSA-N 0.000 description 1
- HNZUNIKWNYHEJJ-UHFFFAOYSA-N geranyl acetone Natural products CC(C)=CCCC(C)=CCCC(C)=O HNZUNIKWNYHEJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP902088A JPH01186835A (ja) | 1988-01-19 | 1988-01-19 | イソプレノイド誘導体およびこれを含有する医薬製剤 |
| EP88908993A EP0380669B1 (en) | 1987-10-16 | 1988-10-14 | Isoprenoid derivatives and pharmaceutical preparation containing same |
| DE3888694T DE3888694T2 (de) | 1987-10-16 | 1988-10-14 | Isoprenoid-derivate und arzneimittelzubereitung, die diese enthält. |
| US07/460,335 US5130483A (en) | 1987-10-16 | 1988-10-14 | Isoprenoid derivatives and pharmaceutical preparations containing the same |
| PCT/JP1988/001046 WO1989003375A1 (en) | 1987-10-16 | 1988-10-14 | Isoprenoid derivatives and pharmaceutical preparation containing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP902088A JPH01186835A (ja) | 1988-01-19 | 1988-01-19 | イソプレノイド誘導体およびこれを含有する医薬製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01186835A true JPH01186835A (ja) | 1989-07-26 |
| JPH0544936B2 JPH0544936B2 (enrdf_load_stackoverflow) | 1993-07-07 |
Family
ID=11708972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP902088A Granted JPH01186835A (ja) | 1987-10-16 | 1988-01-19 | イソプレノイド誘導体およびこれを含有する医薬製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01186835A (enrdf_load_stackoverflow) |
-
1988
- 1988-01-19 JP JP902088A patent/JPH01186835A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0544936B2 (enrdf_load_stackoverflow) | 1993-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0199153A2 (en) | Lipoxygenase inhibiting compounds | |
| WO1993002999A1 (en) | Phenylalkanoic acid derivative, production thereof, and separation of optical isomers thereof | |
| HU203076B (en) | Process for producing arylhydroxamic acid derivatives and pharmaceutical compositions comprising such compounds, as well as composition regulating plant growth and delaying fading of cut flowers | |
| CN101434517A (zh) | 治疗免疫疾病的新的1,2-二苯基乙烯衍生物 | |
| DE68917357T2 (de) | Derivate der Coffeinsäure und pharmazeutische Zusammensetzungen, die sie enthalten. | |
| JPH0748255A (ja) | ピリミドン誘導体及び類似化合物を含有する、喘息又は炎症性気道疾患の治療用医薬組成物 | |
| JPH01186835A (ja) | イソプレノイド誘導体およびこれを含有する医薬製剤 | |
| CN113402414A (zh) | 一种苯甲酸衍生物及其制法和药物用途 | |
| US6803367B2 (en) | Substance for inducing apoptosis | |
| EP0380669B1 (en) | Isoprenoid derivatives and pharmaceutical preparation containing same | |
| JPH08502521A (ja) | １０−置換 １，８−ジヒドロキシ−９（１０ｈ）アントラセノン医薬 | |
| JP2559814B2 (ja) | カテコール誘導体及びこれを含有する医薬製剤 | |
| JPH08217672A (ja) | キサントン誘導体を含有する抗ヘリコバクター・ピロリ薬 | |
| WO1992015543A1 (fr) | Nouveau derive d'alcool allylique | |
| JP2748415B2 (ja) | ヒドロキサム酸誘導体 | |
| JP2819047B2 (ja) | 発癌予防剤 | |
| CN115057856B (zh) | 3,5-二取代-7氮杂吲哚衍生物及其合成方法与应用 | |
| JPH01102043A (ja) | イソプレノイド誘導体およびこれを含有する５−リポキシゲナーゼ作用阻害剤 | |
| JP4448923B2 (ja) | 新規なオルシノール誘導体化合物及びそれを含む医薬組成物 | |
| JPS6115A (ja) | リポキシゲナ−ゼ代謝産物に起因する疾患の予防治療剤 | |
| JP2639568B2 (ja) | 細胞増殖抑制剤 | |
| JPS62258362A (ja) | アミド誘導体およびこれを含有する５−リポキシゲナ−ゼ作用阻害剤 | |
| JPH0353296B2 (enrdf_load_stackoverflow) | ||
| JPS625956A (ja) | ビニル誘導体およびこれを含有する５−リポキシゲナ−ゼ作用阻害剤 | |
| TWI584806B (zh) | 燕麥麴黴素之用途及製備方法 |